GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GeneOne Life Science, Inc.

Criteria

Inclusion Criteria:

• Age 18 or older

• Able to provide informed consent

• Able and willing to comply with study procedures

• Able and willing to utilize an approved form of pregnancy prevention for women of child bearing potential through to the end of treatment

Exclusion Criteria:

• Know allergy to quinine, quinidine, or mefloquine

• Confirmed prior positive test for SARS-CoV-2

• Treatment within the past 2 weeks with chloroquine, hydroxychloroquine, or remdesivir

• Pregnancy or documentation of pregnancy by pre-treatment urine test or breast feeding or plans to become pregnant during the course of the study